Martin Schüler

44.8k citations
478 papers · 20.5k indexed · 7 hit papers · h-index 67

Impact in

  • Oncology top 0.1%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Cancer-related Molecular Pathways
    • Lung Cancer Treatments and Mutations
    • Gastric Cancer Management and Outcomes
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Colorectal Cancer Treatments and Studies 60
    • Lung Cancer Research Studies 46
    • HER2/EGFR in Cancer Research 42
    • Cancer Immunotherapy and Biomarkers 26
    • Lung Cancer Treatments and Mutations 139
    • Lung Cancer Diagnosis and Treatment 32
    • Gastric Cancer Management and Outcomes 29

Martin Schüler

454 papers receiving 20.1k citations

Hit Papers

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial 2022 · 144 citations
144200420262011201850010001.5k2.0k

Peers

Martin Schüler
Comparison fields: 5 of 198
  • Oncology 9.7k
  • Pulmonary and Respiratory Medicine 7.2k
  • Cancer Research 2.9k
  • Molecular Biology 8.9k
  • Immunology 2.0k
Replace Gary K. Schwartz with:
Gary K. Schwartz United States
Jordan Berlin United States
Atsushi Ochiai Japan
Jennifer R. Grandis United States
Christiane J. Bruns Germany
David S. Hong United States
Jeffrey W. Clark United States
Patricia LoRusso United States
Yongping Hao United States
Joseph R. Testa United States
Martin Schüler relative to Gary K. Schwartz United States Gary K. Schwartz's profile →
Citations per field
00.5×1.5×
Gary K. Schwartz · 1×
Citations per year

Countries citing papers authored by Martin Schüler

Since Specialization
Citations

This map shows the geographic impact of Martin Schüler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Schüler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Schüler more than expected).

Fields of papers citing papers by Martin Schüler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Schüler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Schüler. The network helps show where Martin Schüler may publish in the future.

Co-authors

The 25 scholars most cited alongside Martin Schüler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Martin Schüler Line = papers co-authored together Martin Schüler links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20243
2 20240
3 20246
4 20242
5 20241
6 20231
7 20236
8 202316
9 202291
10
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Hit paper breakdown →
2018302
11 20152
12 201480
13
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Hit paper breakdown →
20132461
14 201367
15 2010255
16 200989
17 200974
18 200850
19 200869
20 2004124

About Martin Schüler

Martin Schüler is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Gastroenterology and Anesthesiology and Pain Medicine, having authored 478 papers that have together received 20.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (139 papers), Colorectal Cancer Treatments and Studies (60 papers), Lung Cancer Research Studies (46 papers), HER2/EGFR in Cancer Research (42 papers), Cancer Genomics and Diagnostics (32 papers), Lung Cancer Diagnosis and Treatment (32 papers), Gastric Cancer Management and Outcomes (29 papers) and Cancer Immunotherapy and Biomarkers (26 papers). The work is most often cited by research in Oncology (9.7k citations), Pulmonary and Respiratory Medicine (7.2k citations), Cancer Research (2.9k citations), Molecular Biology (8.9k citations) and Immunology (2.0k citations). Martin Schüler has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Douglas R. Green, Donald D. Newmeyer, Jerry E. Chipuk, James Chih‐Hsin Yang, Lecia V. Sequist, Tony Mok, Nobuyuki Yamamoto, Tomomi Kuwana, Lisa Bouchier‐Hayes and Nathalie Droin. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Cancer Research and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026